Xenon Pharmaceuticals Inc(XENE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:43 PM ET (Korea 10/30 05:43)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.74 | Insider Own | 5.26% | Shs Outstand | 96.8M | Perf Week | 2.74% |
| Market Cap | 3.63B | Forward P/E | - | EPS next Y | -1.77% | Insider Trans | 0.5% | Shs Float | 91.7M | Perf Month | 0.83% |
| Enterprise Value | 2.71B | PEG | - | EPS next Q | -1.13 | Inst Own | 100.49% | Short Float | 8.01% | Perf Quarter | -40.16% |
| Income | -0.41B | P/S | - | EPS this Y | -5.62% | Inst Trans | 2.51% | Short Ratio | 4.98 | Perf Half Y | -33.08% |
| Sales | 0.00B | P/B | 2.92 | EPS next 5Y | 8.32% | ROA | -41.54% | Short Interest | 7.35M | Perf YTD | -16.33% |
| Book/sh | 12.84 | P/C | 3.9 | EPS past 3/5Y | -28.36% -40.02% | ROE | -43.62% | 52W High | -48.39% ($72.66) | Perf Year | -11.35% |
| Cash/sh | 9.61 | P/FCF | - | Sales past 3/5Y | -7.36% -25.26% | ROIC | -32.8% | 52W Low | 12.34% ($33.38) | Perf 3Y | 21.48% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -33.88% | Gross Margin | - | Volatility(W/M) | 3.08% 3.49% | Perf 5Y | 20.39% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 1.49 | Perf 10Y | 360.12% |
| Dividend Ex-Date | - | Quick Ratio | 21.02 | EPS Q/Q | -3.62% | Profit Margin | - | RSI (14) | 44.6 | Recom | 1.16 |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.02 | Sales Q/Q | - | SMA20 | 4.47% ($35.9) | Beta | 0.1 | Target Price | $71.94 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/6 | SMA50 | -18.11% ($45.79) | Rel Volume | 0.94 | Prev Close | $36.34 |
| Employees | 370 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 2.76% -100% | SMA200 | -28.42% ($52.39) | Avg Volume(3M) | 1.48M | Price | $37.5 |
| IPO | 2014/11/5 | Option/Short | Yes/Yes | Trades | 11248 | Volume | 1,387,632 | Change | 3.19% |
🧠 This is a late-stage clinical biotech company developing therapies for neurological disorders. Using a mechanism that modulates ion channels in nerve cells, it is advancing late-stage clinical candidates for neurological and psychiatric conditions such as epilepsy and depression. Its stock price tends to be driven by clinical trial results and regulatory progress for its lead candidate, as well as its funding situation, making it a typical bio-healthcare stock.
Over the past 1 year, on the lower side
48% below its 1-year high.
Traded about as much as usual. That is 94% of its average volume.
XENE has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -5.6% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 5 years ago, your return today would be +20.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 100.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #64 of 594 in the industry
Based on market cap of $4B.
TNGX#62 Tango Therapeutics Inc $4B PER - 
TARS#63 Tarsus Pharmaceuticals Inc $4B PER - XENE#64 Xenon Pharmaceuticals Inc $4B PER - 
ACAD#65 Acadia Pharmaceuticals Inc $4B PER 9.3 
PBLS#66 Parabilis Medicines Inc $4B PER - 
FAQ
What kind of company is XENE?
XENE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XENE?
The market cap of XENE is approximately $3.6B, ranking 1,614 within its sector.
What is the 52-week high and low for XENE?
XENE has recorded a 52-week high of $72.66 and a low of $33.38.
